Genprex

Clinical Trials

R&D Pipeline


Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. We are developing our lead product candidate REQORSA to be administered with targeted therapies and with immunotherapies for NSCLC. We continue to conduct preclinical research to explore how REQORSA may be administered with targeted therapies and immunotherapies in other solid tumors, and we are researching how other cancer fighting genes can be applied using our ONCOPREX Nanoparticle Delivery System. We also are developing our pre-clinical diabetes candidate, GPX-002. The following table summarizes our product development pipeline.

Tagrisso® is a registered trademark of AstraZeneca.

Keytruda® is a registered trademark of Merck.

Tarceva® is a registered trademark of Astellas and the Roche Group of companies.